Table 25:

Prostate Cancer Detection in the Finnish Prostate Cancer Screening Trial

	Screen Arm	Control Arm	RR	95% CI	P Value
Total men randomized, n	31,866	48,278
P-YRs	292,474	449,885
Total PCs, n	2,655	2,796
PC incidence rate	8.3%	5.8%
PC incidence/1,000 P-YRs	9.1	6.2	1.46	1.4–1.5	< 0.001
Incidence localized (T1–2, N0, M0) PC/1,000 P-YRs	7.5	4.6	1.63	1.5–1.7	< 0.001
Incidence advanced (T3–4 or N1 or M1) PC/1,000 P-YRs (all ages)	1.1	1.5	0.69	0.6–0.8	< 0.001
55-year-olds			0.84	0.6–1.2	0.33
59-year-olds			0.79	0.6–1.0	0.09
63-year-olds			0.83	0.6–1.1	0.14
67-year-olds			0.57	0.5–0.7	< 0.001
Incidence low-grade (GS < 7) PC/1,000 P-YRs	5.8 (5.3%)	3.2 (3.0%)	1.82	1.7–1.9	< 0.001
Incidence intermediate-grade (GS = 7) PC/1,000 P-YRs	1.9 (1.7%)	1.8 (1.7%)	1.02	0.9–1.1	0.72
Incidence high-grade (GS = 8–10) PC/1,000 P-YRs	0.8 (0.8%)	0.9 (0.7%)	0.89	0.8–1.0	0.16

Abbreviations: CI, confidence interval; GS, Gleason score; M0, no distant metastasis; M1, distant metastasis present; N0, no regional lymph node involvement; N1, regional lymph node involvement; PC, prostate cancer; P-YR, person-year; RR, relative risk; T, tumour stage.

Source: Kilpelainen et al, 2010. (63)